Inhibition of GSK-3 has been also claimed as a modality to increase c-Myc-driven apoptosis of chemo-resistant Burkitt lymphoma cells, as GSK-3 inhibitors upregulate c-Myc protein half-life via a paradoxical transient attenuation of its proteasomal degradation [173]. Here, MYC is linked to Burkitt lymphoma.